Biocon and Pfizer team up to promote insulin biosimilar

Biocon, Asia's leading biotechnology company, will be teaming up with Pfizer to promote the insulin biosimilars Glargine, Aspart and Lispro throughout the world according to Topinews. This partnerships will represent the companies working together worldwide on manufacturing, marketing and research. Biocon will receive $200 million up front and payments of $150 million in regulatory payments.

David Simmons, president and general manager of Pfizer’s Established Products Business Unit, stated:
"We are excited to join forces with Biocon in the battle against the disease and economic burden that diabetes poses to global health. Our alliance with Biocon will enable the delivery of biosimilar insulin products, providing attractive, cost-effective treatment options to more diabetes patients."

Share this article with your social network, just click below to share now!

Share |